Crescent Biopharma, Inc. (CBIO) financial statements and ratios from SEC XBRL: revenue $10.84M (TTM), net margin -1419.6%, revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $10.84M |
| Net Margin | -1419.6% |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | 1.7% |
| FCF Growth (YoY) | -10.9% |
| Price / Book | 3.91 |
| Price / Sales | 307.27 |
| FCF Yield | -7.3% |
| Altman Z-Score | 5.57 (safe) |
| Sector P/E (Healthcare) | 21.7 |
CBIO overview · CBIO earnings · CBIO KPIs · CBIO investor relations · CBIO ownership · CBIO peers · CBIO filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.